Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

901.19 +7.05 (+0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 468,670
Open 903.88
Bid (Size) 901.18 (1)
Ask (Size) 963.00 (1)
Prev. Close 894.14
Today's Range 899.90 - 911.64
52wk Range 684.80 - 998.33
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... 
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire

Performance

YTD
-0.42%
-0.42%
1 Month
-6.12%
-6.12%
3 Month
-3.85%
-3.85%
6 Month
+7.69%
+7.69%
1 Year
+9.94%
+9.94%

More News

Read More
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
Via Benzinga
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
Via Benzinga
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Via Benzinga
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
Via Benzinga
Topics Fraud
Exposures Legal
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
Via Investor's Business Daily
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Via Benzinga
Should You Sell This Stock Following a Regulatory Roadblock?
Via The Motley Fool
5 Healthcare Stocks to Buy for 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
Via Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading
Via Investor Brand Network
Regeneron Pharmaceuticals Unusual Options Activity For March 20
Via Benzinga
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Via The Motley Fool
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
Via InvestorPlace
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
Via Benzinga
Exposures Product Safety
Regeneron Provides Update on Biologics License Application for Odronextamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.